Acura Pharmaceuticals, Inc. is an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications.

We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our LIMITX™ Technology is intended to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. Our AVERSION® Technology is intended to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Our IMPEDE® Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
 

• Our LIMITX™ Technology, is currently in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidate. This is due to the large market size and prevalence of oral excessive abuse and overdose. This technology is designed to retard the release of active opioid drug when too many tablets are accidentally or purposefully ingested by neutralizing stomach acid with buffer ingredients but deliver efficacious amounts of drug when taken as a single tablet with a nominal buffer dose. U.S. commercialization rights to LTX-03 are licensed to Abuse Deterrent Pharmaceuticals LLC.

• Our AVERSION® Technology is licensed to Zyla Life Sciences (formerly known as Egalet Corporation) for use in OXAYDO® Tablets (oxycodone HCl, CII), and is the first approved immediate-release oxycodone product in the United States with abuse deterrent labeling. OXAYDO® is currently approved by the FDA for marketing in the United States in 5mg and 7.5mg strengths.

• Our IMPEDE® Technology is used in Nexafed® (30mg pseudoephedrine HCl) and Nexafed® Sinus Pressure + Pain Tablets (pseudoephedrine HCl/acetaminophen 30/325mg tablets). We have licensed our Impede® Technology to MainPointe Pharmaceuticals LLC for commercialization of these Nexafed® products in the United States and Canada.